Fsd Pharma (TSE:HUGE) has released an update.
FSD Pharma has announced the submission of their Phase-1 multiple ascending dose clinical trial for Lucid-21-302, a novel treatment for multiple sclerosis, to an Australian ethics committee for review. This submission follows a successful single dose trial, and the company is hopeful about the compound’s unique non-immunomodulatory and neuroprotective properties. If approved, this will pave the way for Phase-2 trials and further development of what could be a groundbreaking treatment for neurodegenerative diseases.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
